Dmitry Balyasny’s AEON Biopharma AEON Stock Holding History

Dmitry Balyasny’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,106	Closed	-$2.25M	–	2589
2022 Q4	$2.25M	Hold	3,106	–	–	0.01%	1366
2022 Q3	$2.2M	Buy	3,106 +328	+12%	+$232K	0.01%	1443
2022 Q2	$1.96M	Hold	2,778	–	–	0.01%	1423
2022 Q1	$1.96M	Hold	2,778	–	–	0.01%	1378
2021 Q4	$1.94M	Hold	2,778	–	–	0.01%	1255
2021 Q3	$1.95M	Hold	2,778	–	–	0.01%	1136
2021 Q2	$1.93M	Buy	+2,778	New	+$1.94M	0.01%	1041

Other funds holding AEON

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $129M AUM 16.02% 1-Year Est. Return

Dmitry Balyasny's AEON Position: Q1 2023 in Review

Dmitry Balyasny sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 3,106 shares — an estimated $2.25M sold.

Dmitry Balyasny first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $2.25M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Dmitry Balyasny reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Dmitry Balyasny sold 3,106 AEON Biopharma shares in Q1 2023, an estimated $2.25M.
Dmitry Balyasny first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
Dmitry Balyasny's AEON Biopharma position peaked at $2.25M in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.